Literature DB >> 30012776

Microdialysis Study of Aztreonam-Avibactam Distribution in Peritoneal Fluid and Muscle of Rats with or without Experimental Peritonitis.

Alexia Chauzy1, Isabelle Lamarche1, Christophe Adier1,2, William Couet1,2, Sandrine Marchand3,2.   

Abstract

The purpose of this study was to investigate aztreonam (ATM) and avibactam (AVI) distribution in intraperitoneal fluid and muscle interstitial fluid by microdialysis in rats, with or without peritonitis, and to compare the unbound concentrations in tissue with the unbound concentrations in blood. Microdialysis probes were inserted into the jugular veins, hind leg muscles, and peritoneal cavities of control rats (n = 5) and rats with intra-abdominal sepsis (n = 9) induced by cecal ligation and punctures. ATM and AVI probe recoveries in each medium were determined for both molecules in each rat by retrodialysis by drug. ATM-AVI combination was administered as an intravenous bolus at a dose of 100-25 mg · kg-1 Microdialysis samples were collected over 120 min, and ATM-AVI concentrations were determined by liquid chromatography-tandem mass spectrometry. Noncompartmental pharmacokinetic analysis was conducted and nonparametric tests were used for statistical comparisons between groups (infected versus control) and medium. ATM and AVI distribution in intraperitoneal fluid and muscle was rapid and complete both in control rats and in rats with peritonitis, and the concentration profiles in blood, intraperitoneal fluid, and muscle were virtually superimposed, in control and infected animals, both for ATM and AVI. No statistically significant difference was observed between unbound tissue extracellular fluid and systemic areas under the curve for both molecules in control and infected animals. In the present study, intraperitoneal infection induced by cecal ligation and puncture had no apparent effect on ATM and AVI pharmacokinetics in rats.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  aztreonam-avibactam; intraperitoneal infection; microdialysis; pharmacokinetics

Mesh:

Substances:

Year:  2018        PMID: 30012776      PMCID: PMC6153784          DOI: 10.1128/AAC.01228-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  The ability of fluconazole to penetrate into ventilated, healthy and inflamed lung tissue in a model of severe sepsis in rats.

Authors:  Oliver Mauric; Christiane Thallinger; Sylvia A Kugler; Samir M Joukhadar; Florian M Kovar; Karl H Konz; Wolfgang Graninger; Christian Joukhadar
Journal:  Pharmacology       Date:  2011-02-10       Impact factor: 2.547

2.  Kinetics of imipenem distribution into the peritoneal fluid of patients with severe peritonitis studied by microdialysis.

Authors:  Claire Dahyot-Fizelier; Sandrine Lefeuvre; Leila Laksiri; Sandrine Marchand; Ronald J Sawchuk; William Couet; Olivier Mimoz
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

3.  Concurrent determination of thalidomide in rat blood, brain and bile using multiple microdialysis coupled to liquid chromatography.

Authors:  Yu-Jen Huang; Jyh-Fei Liao; Tung-Hu Tsai
Journal:  Biomed Chromatogr       Date:  2005-09       Impact factor: 1.902

Review 4.  Physiological parameters in laboratory animals and humans.

Authors:  B Davies; T Morris
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

5.  Microdialysis study of imipenem distribution in skeletal muscle and lung extracellular fluids of noninfected rats.

Authors:  Sandrine Marchand; Claire Dahyot; Isabelle Lamarche; Olivier Mimoz; William Couet
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

6.  Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.

Authors:  Iris K Minichmayr; André Schaeftlein; Joseph L Kuti; Markus Zeitlinger; Charlotte Kloft
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

Review 7.  A review of the pharmacokinetics and pharmacodynamics of aztreonam.

Authors:  Christopher Ramsey; Alasdair P MacGowan
Journal:  J Antimicrob Chemother       Date:  2016-06-21       Impact factor: 5.790

8.  Comparison of piperacillin exposure in the lungs of critically ill patients and healthy volunteers.

Authors:  T W Felton; K Ogungbenro; E Boselli; W W Hope; K A Rodvold
Journal:  J Antimicrob Chemother       Date:  2018-05-01       Impact factor: 5.790

9.  Comparative pharmacokinetics of carumonam and aztreonam in mice, rats, rabbits, dogs, and cynomolgus monkeys.

Authors:  Y Kita; T Fugono; A Imada
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

10.  Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.

Authors:  Joseph S Solomkin; John E Mazuski; John S Bradley; Keith A Rodvold; Ellie J C Goldstein; Ellen J Baron; Patrick J O'Neill; Anthony W Chow; E Patchen Dellinger; Soumitra R Eachempati; Sherwood Gorbach; Mary Hilfiker; Addison K May; Avery B Nathens; Robert G Sawyer; John G Bartlett
Journal:  Clin Infect Dis       Date:  2010-01-15       Impact factor: 9.079

View more
  1 in total

1.  MIC profiling of ceftazidime/avibactam against two carbapenemase-producing Klebsiella pneumoniae isolates.

Authors:  Andrei Zidaru; Brianna M Eales; Weiqun Wang; Paul R Merlau; Todd M Lasco; Amelia K Sofjan; Vincent H Tam
Journal:  J Glob Antimicrob Resist       Date:  2020-11-06       Impact factor: 4.035

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.